Imaging Markers of Disease Progression in Multiple System Atrophy

References

• BowerJH, MaraganoreDM, McDonnellSK, RoccaWA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology49(5), 1284–1288 (1997).
   PubMed Web of Science ®Google Scholar
• SchragA, Ben-ShlomoY, QuinnNP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet354(9192), 1771–1775 (1999).
   PubMed Web of Science ®Google Scholar
• KrismerF, WenningGK. Multiple system atrophy: insights into a rare and debilitating movement disorder. Nat. Rev. Neurol.13(4), 232–243 (2017).
   PubMed Web of Science ®Google Scholar
• PoeweW, MahlknechtP, KrismerF. Therapeutic advances in multiple system atrophy and progressive supranuclear palsy. Mov. Disord.30(11), 1528–1538 (2015).
   PubMed Web of Science ®Google Scholar
• KrismerF, SeppiK, StefanovaN, WenningGK. Toward disease modification in multiple system atrophy: pitfalls, bottlenecks, and possible remedies. Mov. Disord.31(2), 235–240 (2016).
   PubMed Web of Science ®Google Scholar
• HeimB, KrismerF, SeppiK. Structural imaging in atypical Parkinsonism. Int. Rev. Neurobiol.142, 67–148 (2018).
   PubMed Web of Science ®Google Scholar
• HeimB, KrismerF, DeMarzi R, SeppiK. Magnetic resonance imaging for the diagnosis of Parkinson's disease. J. Neural. Transm. (Vienna)124(8), 915–964 (2017).
   PubMed Web of Science ®Google Scholar
• MahlknechtP, HotterA, HusslA, EsterhammerR, SchockeM, SeppiK. Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. Neurodegener. Dis.7(5), 300–318 (2010).
   PubMed Web of Science ®Google Scholar
• RizzoG, ZanigniS, DeBlasi Ret al.Brain MR contribution to the differential diagnosis of Parkinsonian syndromes: an update. Parkinsons Dis.2983638 (2016).
   PubMed Web of Science ®Google Scholar
• StoesslAJ, LehericyS, StrafellaAP. Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. Lancet384(9942), 532–544 (2014).
   PubMed Web of Science ®Google Scholar
• NockerM, SeppiK, DonnemillerEet al.Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]beta-CIT SPECT. Eur. J. Nucl. Med. Mol. Imaging39(6), 1012–1020 (2012).
   PubMed Web of Science ®Google Scholar
• DodelR, SpottkeA, GerhardAet al.Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov. Disord.25(1), 97–107 (2010).
   PubMed Web of Science ®Google Scholar
• LeePH, LeeJE, KimHSet al.A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann. Neurol.72(1), 32–40 (2012).
   PubMed Web of Science ®Google Scholar
• WildEJ, FoxNC. Serial volumetric MRI in Parkinsonian disorders. Mov. Disord.24(Suppl 2), S691–S698 (2009).
   PubMedGoogle Scholar
• BrenneisC, EggerK, ScherflerCet al.Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study. J. Neurol.254(2), 191–196 (2007).
   PubMed Web of Science ®Google Scholar
• MinneropM, LudersE, SpechtKet al.Callosal tissue loss in multiple system atrophy – a one-year follow-up study. Mov. Disord.25(15), 2613–2620 (2010).
   PubMed Web of Science ®Google Scholar
• SunwooMK, YunHJ, SongSKet al.Mesenchymal stem cells can modulate longitudinal changes in cortical thickness and its related cognitive decline in patients with multiple system atrophy. Front. Aging Neurosci.6, 118 (2014).
   PubMed Web of Science ®Google Scholar
• SchottJM, SimonJE, FoxNCet al.Delineating the sites and progression of in vivo atrophy in multiple system atrophy using fluid-registered MRI. Mov. Disord.18(8), 955–958 (2003).
   PubMed Web of Science ®Google Scholar
• PaviourDC, PriceSL, JahanshahiM, LeesAJ, FoxNC. Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain129(Pt 4), 1040–1049 (2006a).
   PubMedGoogle Scholar
• PaviourDC, PriceSL, LeesAJ, FoxNC. MRI derived brain atrophy in PSP and MSA-P. Determining sample size to detect treatment effects. J. Neurol.254(4), 478–481 (2007).
   PubMed Web of Science ®Google Scholar
• ReginoldW, LangAE, MarrasC, HeynC, AlharbiM, MikulisDJ. Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat. Disord.20(2), 222–225 (2014).
   PubMed Web of Science ®Google Scholar
• GuevaraC, BulatovaK, BarkerGJ, GonzalezG, CrossleyN, KemptonMJ. Whole-brain atrophy rate in idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Parkinsons Dis.2016, 9631041 (2016).
   PubMed Web of Science ®Google Scholar
• PellecchiaMT, BaroneP, VicidominiCet al.Progression of striatal and extrastriatal degeneration in multiple system atrophy: a longitudinal diffusion-weighted MR study. Mov. Disord.26(7), 1303–1309 (2011).
   PubMed Web of Science ®Google Scholar
• SeppiK, SchockeMF, MairKJet al.Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. Neuroimage31(1), 240–245 (2006).
   PubMed Web of Science ®Google Scholar
• PoeweW, SeppiK, Fitzer-AttasCJet al.Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol.14(2), 145–152 (2015).
   PubMed Web of Science ®Google Scholar
• KrismerF, SeppiK, WenningGKet al.Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. Parkinsonism Relat. Disord.58, 23–27 (2018).
   PubMed Web of Science ®Google Scholar
• LowPA, ReichSG, JankovicJet al.Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol.14(7), 710–719 (2015).
   PubMed Web of Science ®Google Scholar
• WenningGK, GeserF, KrismerFet al.The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol.12(3), 264–274 (2013).
   PubMed Web of Science ®Google Scholar
• LowPA, RobertsonD, GilmanSet al.Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol.13(3), 268–275 (2014).
   PubMed Web of Science ®Google Scholar
• MatsushimaM, YabeI, ObaKet al.Comparison of different symptom assessment scales for multiple system atrophy. Cerebellum15(2), 190–200 (2016).
   PubMed Web of Science ®Google Scholar
• PaviourDC, PriceSL, JahanshahiM, LeesAJ, FoxNC. Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations. Mov. Disord.21(7), 989–996 (2006b).
   PubMed Web of Science ®Google Scholar
• Van BelleG, MartinDC. Sample size as a function of coefficient of variation and ratio of means. Am. Stat. (47)3, 165–167 (1993).
   Google Scholar
• PayanCA, VialletF, LandwehrmeyerBGet al.Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS – Parkinson Plus Scale. PLoS ONE6(8), e22293 (2011).
   PubMed Web of Science ®Google Scholar